1. high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count \<25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. 2. sustained systolic blood pressure \< 90 mmhg considered to be clinically significant 3. persistent egfr \<20 ml/min/1.73m2 4. known severe liver disease (e.g. bilirubin \>3.5 mg/dl (60 umol/l)) 5. life expectancy estimated to be \< 72 hours based on current clinical condition 6. anticipated hospital discharge or transfer within 5 days based on current clinical condition 7. known anti-phospholipid syndrome 8. unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) 9. participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

1. high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count \<25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. 2. sustained systolic blood pressure \< 90 mmhg considered to be clinically significant 3. persistent egfr \<20 ml/min/1.73m2 4. known severe liver disease (e.g. bilirubin \>3.5 mg/dl (60 umol/l)) 5. life expectancy estimated to be \< 72 hours based on current clinical condition 6. anticipated hospital discharge or transfer within 5 days based on current clinical condition 7. known anti-phospholipid syndrome 8. unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) 9. participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. sustained systolic blood pressure < 90 mmhg considered to be clinically significant persistent egfr <20 ml/min/1.73m2 known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) life expectancy estimated to be < 72 hours based on current clinical condition anticipated hospital discharge or transfer within 5 days based on current clinical condition known anti-phospholipid syndrome unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. sustained systolic blood pressure < 90 mmhg considered to be clinically significant persistent egfr <20 ml/min/1.73m2 known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) life expectancy estimated to be < 72 hours based on current clinical condition anticipated hospital discharge or transfer within 5 days based on current clinical condition known anti-phospholipid syndrome unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

1. high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. 2. sustained systolic blood pressure < 90 mmhg considered to be clinically significant 3. persistent egfr <20 ml/min/1.73m2 4. known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) 5. life expectancy estimated to be < 72 hours based on current clinical condition 6. anticipated hospital discharge or transfer within 5 days based on current clinical condition 7. known anti-phospholipid syndrome 8. unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) 9. participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

1. high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. 2. sustained systolic blood pressure < 90 mmhg considered to be clinically significant 3. persistent egfr <20 ml/min/1.73m2 4. known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) 5. life expectancy estimated to be < 72 hours based on current clinical condition 6. anticipated hospital discharge or transfer within 5 days based on current clinical condition 7. known anti-phospholipid syndrome 8. unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) 9. participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. sustained systolic blood pressure < 90 mmhg considered to be clinically significant persistent egfr <20 ml/min/1.73m2 known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) life expectancy estimated to be < 72 hours based on current clinical condition anticipated hospital discharge or transfer within 5 days based on current clinical condition known anti-phospholipid syndrome unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, recent hemorrhagic stroke, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current therapeutic anticoagulation for a medical indication other than covid-19, e.g. atrial fibrillation, known thrombosis, hereditary or acquired coagulopathy treated with therapeutic anticoagulation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. sustained systolic blood pressure < 90 mmhg considered to be clinically significant persistent egfr <20 ml/min/1.73m2 known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) life expectancy estimated to be < 72 hours based on current clinical condition anticipated hospital discharge or transfer within 5 days based on current clinical condition known anti-phospholipid syndrome unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) participation in any interventional clinical study with an investigational product within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

1. high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current anticoagulation for a medical indication. e.g. atrial fibrillation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. 2. sustained systolic blood pressure < 90 mmhg considered to be clinically significant 3. persistent egfr <20 ml/min/1.73m2 4. known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) 5. life expectancy estimated to be < 72 hours based on current clinical condition 6. anticipated hospital discharge or transfer within 72 hours based on current clinical condition 7. known anti-phospholipid syndrome 8. unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) 9. participation in a clinical study or treatment with an investigational drug or device, defined as one not approved for any indication in the us, europe or japan, within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer

1. high bleeding risk, e.g. major surgery within prior 1 month, history of a major bleed while receiving anticoagulation, current or planned (during current hospitalization) dual anti-platelet therapy, platelet count <25,000/ul, current anticoagulation for a medical indication. e.g. atrial fibrillation. patients receiving prophylactic anticoagulation are eligible if they are willing to discontinue current anticoagulation. 2. sustained systolic blood pressure < 90 mmhg considered to be clinically significant 3. persistent egfr <20 ml/min/1.73m2 4. known severe liver disease (e.g. bilirubin >3.5 mg/dl (60 umol/l)) 5. life expectancy estimated to be < 72 hours based on current clinical condition 6. anticipated hospital discharge or transfer within 72 hours based on current clinical condition 7. known anti-phospholipid syndrome 8. unable to receive heparin, e.g. history of heparin-induced thrombocytopenia and thrombosis (hitt) 9. participation in a clinical study or treatment with an investigational drug or device, defined as one not approved for any indication in the us, europe or japan, within seven (7) days of the screening assessment or within 5 half-lives of the investigational agent, whichever is longer